Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Corporate Update (February 2026)
10 slides from Aroa Biosurgery's corporate update, Feb 3, 2026
Slide 1: Aroa Biosurgery (ARX) – February 2026 Business Update
Aroa Biosurgery (ARX) – February 2026 BUSINESS UPDATE UNLOCKING REGENERATIVE HEALING FOR EVERY BODY 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (Presentation) is dated 3 February 2026 and has been prepared by presentation in conjunction with AROA’s other periodic and continuous disclosure Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 announcements lodged with ASX
Slide 3: Contents
CONTENTS 01 Myriad trauma study 02 Symphony reimbursement 03 Symphony commercial strategy 04 Momentum 05 Guidance 3
Slide 4: Myriad Trauma Study
Myriad Trauma Study MASTRR - the largest ongoing, prospective, multicenter 01 observational study of bioscaffolds in complex reconstruction - 450 patients are enrolled to date. Trauma subgroup - 49 patients (61 defects) in four U.S. Level 1 02 trauma centers. Fully vascularized tissue coverage in a
Slide 5: Symphony reimbursement
Symphony reimbursement 01 Flat fee of 127.14/cm2 from 1st January ‘26 LCDs withdrawn removing limitation on number of 02 applications and requirement for RCT. Expect both to be introduced in the future in some form. Market disruption expected based on new pricing & likely 03 introduction of RCT requ
Slide 6: Symphony commercial strategy
Symphony commercial strategy Hospital Outpatient Department likely to benefit from 01 reimbursement changes – fits with AROA’s direct sales call point Symphony is an important addition to direct team’s sales 02 portfolio Expansion opportunities through distribution partnerships 03 (Physician office,
Slide 7: Momentum
Momentum 01 Increasing success with Myriad in soft tissue reconstruction 02 AROA ECM clinical evidence accumulating 03 Symphony is a significant new opportunity 04 TELABio continues to be significant contributor | Confidential. Not for distribution. 7
Slide 8: Guidance - towards the upper end
Guidance - towards the upper end NZ$92-100m NZ$5-8m Total Revenue Normalised EBITDA YoY CC growth 10 – 20% (Myriad 25%+ YoY CC growth) Note: Guidance provided on constant currency basis (removes the impact of exchange rate movements). Guidance based on an average NZ$/US$ exchange rate of 0.60 (compa
Slide 9: Questions & Answers
AROA BIOSURGERY Questions & Answers 9
Slide 10: Thank you for attending
Thank you for attending Eleonora de Vos m +61 450 930 010 investor@aroa.com Visit www.aroa.com www.linkedin.com/company /aroa-biosurgery-limited/ 64 Richard Pearse Drive, Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand 10